Investigating the Development, Commercialization and Use of Immunotherapeutic Products

According to GLOBOCAN, over twelve billion people worldwide were believed to have cancer in 2008 and in the same year, cancer accounted for 7.5 million deaths worldwide. Furthermore, according to the American Cancer Society, 1 in 4 deaths in the US can be attributed to cancer. With such a staggering number of people affected by cancer, clinical development of therapies that may have a beneficial impact on outcomes is critical.

An estimated 130 potential cancer vaccine are now being studied, many in advanced clinical trials. This ship is setting sail and your company won’t want to be the last to jump on board.

Those in Attendance will Include:

  • Presidents
  • Chief Executive Officers
  • Chief Scientific Officers
  • Chief Technology Officers
  • VP of Immunology
  • VP of Immunotherapy
  • VP of Vaccines
  • Oncologists
  • Pharmacologist
  • Virologsts
  • Physician Researcher
  • Translational Researcher

What’s in it for you?

  • Insight from top immunotherapy leaders spearheading the industry
  • Thoughts from both early and late stage anticancer companies
  • Up to 18 hours of training including interactive panel discussions
  • Networking opportunities with industry leaders
  • Exclusive online access to presentations for 3 months
  • Opportunities to interact with leading experts and service providers
  • Learning material to assist you in your crucial role moving forward

Testimonials

Immunotherapy is evolving so rapidly that meeting attendance and interactions with other investigators is essential if you are going to stay current in the field – John Rothman, PhD, Exec. VP: Science and Operations, Advaxis Inc.
Working in this vastly unproven field, its important to share ideas and strategies to leverage best practices – Mohamed Hussein, MD, Vice President, Medical Affairs, Celgene
Sponsors and Exhibitors Media Partners
imudex-logo _media

[ Register Now ]